According to a new major clinical trial known as the ESSENCE trial, semaglutide—better known as Ozempic when used for Type 2 ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

Fatty liver disease, also called metabolic dysfunction-associated steatohepatitis (MASH), is a condition where fat ...

Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

MASH is typically linked to obesity and often to type 2 diabetes. In a trial in 2020 involving 320 people, Newsome and his colleagues found that a daily semaglutide injection led to reduced liver ...

A major international study has found that semaglutide, a drug already used to treat type 2 diabetes and obesity, can ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...